Analysis of susceptibility factors forinfection with Talaromyces marneffei in non-HIV individuals

Abstract

Abstract: Objective To analyze the immune-related susceptibility factors of Talaromyces marneffei infection (TSM) in non-HIV patients, so as to improve the understanding and management of this disease among clinicians. Methods The clinical characteristics of HIV-negative patients diagnosed with TSM from 2012 to 2021 in Guangxi and other provinces and cities in China collected by our group were prospectively studied to analyse their immune-related susceptibility factors. Results 154 patients were included, and immunodeficiency was detected in 132 cases. Primary immunodeficiency diseases predominated in pediatric patients; immunodeficiency syndrome associated with anti-interferon-gamma autoantibodies predominated in adult patients, and the remainder included co-morbid malignancies and underlying diseases such as connective tissue disease. Conclusion TSM can occur in non-HIV patients with different forms of immunodeficiency and a complete immune status assessment strategy based on susceptibility factors should be established to improve patient prognosis.

Key words: Talaromyce marneffei, HIV-negative, primary immunodeficiency, anti-interferon-gamma autoantibodies

CLC Number:

R519.8

LI Tiantian, LI Bingkun, HUANG Xiaolu, LIAO Liuwei, JIANG Zhiwen, HE Xiaojuan, MO Nanfang, LI Xiuying, JIANG Li, PAN Kaisu, CAO Cunwei. Analysis of susceptibility factors forinfection with Talaromyces marneffei in non-HIV individuals[J]. Chinese Journal of Mycology, 2023, 18(2): 97-103,110.

References

[1] CAO C, XI L, CHATURVEDI V. Talaromycosis (Penicilliosis) due to Talaromyces (Penicillium) marneffei:Insights into the clinical trends of a major fungal disease 60 years after the discovery of the pathogen[J]. Mycopathologia, 2019, 184(6):709-720.
[2] HU Y, ZHANG J, LI X, et al. Penicillium marneffei infection:an emerging disease in mainland China[J]. Mycopathologia, 2013, 175(1-2):57-67.
[3] HE L, MEI X, LU S, et al. Talaromyces marneffei infection in non-HIV-infected patients in mainland China[J]. Mycoses, 2021, 64(10):1170-1176.
[4] GUO J, NING X Q, DING J Y, et al. Anti-IFN-gamma autoantibodies underlie disseminated Talaromyces marneffei infections[J]. J Exp Med, 2020, 217(12):e20190502.
[5] THOMPSON G R, 3RD, LE T, CHINDAMPORN A, et al. Global guideline for the diagnosis and management of the endemic mycoses:an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology[J]. Lancet Infect Dis, 2021, 21(12):e364-e374.
[6] LEE P P, LAO-ARAYA M, YANG J, et al. Application of flow cytometry in the diagnostics pipeline of primary immunodeficiencies underlying disseminated Talaromyces marneffei infection in HIV-Negative Children[J]. Front Immunol, 2019, 10:2189.DOI:10.3389/fimmu.2019.02189.
[7] CHAN J F, LAU S K, YUEN K Y, et al. Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients[J]. Emerg Microbes Infect, 2016, 5(3):e19.
[8] TANG B S, CHAN J F, CHEN M, et al. Disseminated penicilliosis, recurrent bacteremic nontyphoidal salmonellosis, and burkholderiosis associated with acquired immunodeficiency due to autoantibody against gamma interferon[J]. Clin Vaccine Immunol, 2010, 17(7):1132-1138.
[9] PITHUKPAKORN M, ROOTHUMNONG E, ANGKASEKWINAI N, et al. HLA-DRB1 and HLA-DQB1 are associated with adult-onset immunodeficiency with acquired anti-interferon-Gamma autoantibodies[J]. PLoS One, 2015, 10(5):e0128481.
[10] CHI C Y, CHU C C, LIU J P, et al. Anti-IFN-gamma autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection[J]. Blood, 2013, 121(8):1357-1366.
[11] KU C L, LIN C H, CHANG S W, et al. Anti-IFN-gamma autoantibodies are strongly associated with HLA-DR*15:02/16:02 and HLA-DQ*05:01/05:02 across Southeast Asia[J]. J Allergy Clin Immunol, 2016, 137(3):945-948.e8.
[12] CHAWANSUNTATI K, RATTANATHAMMETHEE K, WIPASA J. Minireview:Insights into anti-interferon-gamma autoantibodies[J]. Exp Biol Med (Maywood), 2021, 246(7):790-5.
[13] CHI C Y, LIN C H, HO M W, et al. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-gamma autoantibodies and disseminated nontuberculous mycobacterial infections[J]. Medicine (Baltimore), 2016, 95(25):e3927.
[14] NOMA K, MIZOGUCHI Y, TSUMURA M, et al. Mendelian susceptibility to mycobacterial diseases:state of the art[J]. Clin Microbiol Infect, 2022,28(11):1429-1434.
[15] BOUSFIHA A, JEDDANE L, PICARD C, et al. Human inborn errors of immunity:2019 update of the IUIS phenotypical classification[J]. J Clin Immunol, 2020, 40(1):66-81.